Singapore’s MerLion Completes Phase II Finafloxacin Urinary Tract Infection Trial Recruitment
This article was originally published in The Pink Sheet Daily
Executive Summary
The Singapore-based firm continues to push ahead on new applications for its finafloxacin antibiotic even as it searches for more funding to carry out work that can bring about regulatory approvals and cash flow.